U.S. stock market update: Ernexa Therapeutics stock price plummets 17.13%, market sentiment shifts dramatically after preclinical data breakthrough!

U.S. Stock Market Midday Update Ernexa Therapeutics fell 17.13%. Based on recent key news: On May 11, Ernexa Therapeutics announced in the EDGAR system regarding the company's latest breakthrough in preclinical data, which drove the stock price up. This announcement attracted market attention, leading to significant stock price fluctuations on May 12. On May 12, Ernexa's stock price surged significantly after breaking through preclinical data, reaching $10.67, an increase of 47.99%. This rise was mainly influenced by investors' optimistic expectations for the company's future development. On May 13, technical analysis showed Ernexa's stock price fluctuating between key support at $5.80 and resistance at $7.49, with market uncertainty regarding its future trend. The biotechnology industry has been volatile recently and requires attention. Stocks with High Trading Volume in the Industry Quantum Cyber NV rose 94.80%. Based on recent key news: On May 13, Quantum Cyber secured an exclusive drone platform contract, coinciding with the U.S. government's search for $55 billion in drone combat funding. This news significantly boosted the stock price and increased trading volume. Source: Reuters On May 14, Quantum Cyber announced the addition of a senior retired U.S. military official to the company, enhancing its expertise in defense and capital markets. This personnel change was seen as significant support for the company's drone platform, further driving the stock price up. Source: Benzinga On May 14, technical indicators showed the stock price was overbought, with an RSI of 82.42, suggesting strong market demand but increased volatility risk. The stock price broke through the 52-week high, reaching a new resistance level. Source: Benzinga The demand in the drone industry is strong, with noticeable capital inflow. AbbVie rose 1.15%, with increased trading volume. Based on recent key news: On May 14, AbbVie's management predicted strong revenue and profit margin growth in the coming years, primarily driven by core products such as SKYRIZI and RINVOQ. This news boosted market confidence and drove the stock price up. Source: MarketBeat On May 12, AbbVie achieved a significant milestone in the second quarter, expected to provide funding support for the company's operations until early 2028. This financial stability enhanced investor confidence, promoting the stock price increase. Source: SEC filings On May 12, AbbVie's drug portfolio and 3.4% dividend growth attracted investor attention, further driving the stock price up. Source: MarketBeat The industry is experiencing strong growth, with a stable macroeconomic environment Biogen fell 5.22%. Based on recent key news: On May 14, Biogen announced that its Alzheimer's drug diranersen failed to meet primary endpoints in mid-stage trials, but it still decided to advance to late-stage clinical trials. This news led to a decline in stock price due to increased market concerns about the drug's efficacy. On May 14, Biogen completed its acquisition of Apellis, which is expected to enhance future revenue growth and have a positive impact on non-GAAP diluted earnings per share. Nevertheless, the stock price remained under pressure due to poor trial results. On May 14, analyst Phil Nadeau maintained a buy rating on Biogen with a target price of $215, indicating market confidence in the company's long-term prospects, but the stock price is still affected by trial results in the short term. The biopharmaceutical industry faces R&D risks. Stocks ranked at the top of the industry by market capitalization Amgen rose 0.12%. Based on recent key news: On May 14, Piper Sandler lowered Amgen's target price from $432 to $427, leading to weakened market confidence in its future performance and putting pressure on the stock price. On May 13, MarketBeat reported that analysts rated Amgen as hold and believed there are five other stocks with greater investment value, which may affect investor interest in Amgen. On May 12, Amgen was listed as one of the strong stocks during inflationary periods due to its high dividend yield and reliability, attracting some investor attention. Inflation-resistant stocks are receiving noticeable inflows